Brave messages for a goal to eliminate hepatitis C
DOI:
https://doi.org/10.24197/aramcv.56.2020.70-78Abstract
VHC is a Ribovirus which belongs to Flaviviridae family and Hepaciviral gender; it´s clasificated in seven main genotypes and nearly of 90 subtypes have been detected until 2017.
The challenger of minimizing or reducing the transmission is important.
The elimination of Hepatitis can be only possible if the effectiveness of new treatment and Public Health Politics can be combinated; prioritized the non-diagnosed patients and Universal access for the treatment.
Downloads
References
http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=[consultado 15 de junio de 2019]
http://aeeh.es/wp-content/uploads/2017/02/Recomendaciones-hepatitis-C-en-Atenci%C3%B3n-Primaria.pdf [consultado13 de junio de 2019]
https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf [consultado 13 de junio de 2019]
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017 Jun 6; 6: CD012143. doi: 10.1002/14651858.CD012143.pub2.
Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol. 2017 May 25 :1-18. doi: 10.1080/1040841X.2017.1329277
Wang S, Wang Y, Wang J, Sato T, Izawa K, Soloshonok VA, Liu H. The second-generation of highly potent hepatitis C virus (HCV) NS3/4A protease inhibitors: Evolutionary design based on tailor-made amino acids, synthesis and major features of bio-activity. Curr Pharm Des. 2017 May 22. doi: 10.2174/1381612823666170522122424.
Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17: 1215-23.
Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017; 66: 703-710.
Gelson W, Alexander G. Is elimination of hepatitis C from the UK by 2030 a realistic goal? Br Med Bull. 2017 Jun 9:1-9. doi: 10.1093/bmb/ldx017
Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015; 113: 31-44.
Buti M, Calleja JL, García Samaniego J, Serra MA, Crespo J, Romero M et al. Eliminación de la hepatitis C en España: adaptación de un modelo matemático de salud pública partiendo del plan estratégico para el abordaje de la hepatitis C en el sistema Nacional de la Saluded Clin (Barc) 2017; 148: 277-282.
http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care consultado 15 de junio de 2019]
Bregenzer A, Conen A, Knuchel J, Friedl A, Eigenmann F, Näf M, et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Swiss Med Wkly. 2017; 147: w14544. doi:10.4414/smw.2017.14544
Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis. 2017 ;17(Suppl 1): 699.
Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. 2017; doi: 10.1111/jvh.12827.
Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ. 2017 :1-10. doi: 10.1080/13696998.2017.1369983.
Bethea E, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2017. doi: 10.1002/hep.29611.
He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017; 46: 711-721.
Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017; 47: 107-116.
Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low- and middle-income countries. BMC Infect Dis. 2017; 17(Suppl 1): 697. doi: 10.1186/s12879-017-2779-9.
Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, et al. Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis. J Viral Hepat. 2017. doi: 10.1111/jvh.12846.
Cacoub P, Vautier M, Desbois AC, Saadoun D, Younossi Z. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. Aliment Pharmacol Ther. 2018; 47: 123-128.
http://www.un.org/sustainabledevelopment/es/2015/09/la-asamblea-general-adopta-la-agenda-2030-para-el-desarrollo-sostenible/[consultado 16 de diciembre de 2019]
Connolly MP, Kotsopoulos N, Ustianowski A. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic Hepatitis C. J Med Econ. 2017 Sep 5: 1-8. doi: 10.1080/13696998.2017.1371032.
Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat. 2015; 22 Suppl 1:1-5. doi: 10.1111/jvh.12371.
Marinho RT, Vitor S, Velosa J. Benefits of curing hepatitis C infection. J Gastrointestin Liver Dis. 2014; 23: 85-90.
http://www.plataformadeafectadosporhepatitisc.org/[consultado 16 de diciembre de 2019].
https://www.msssi.gob.es/organizacion/consejoInterterri/docs/od2015.pdf [consultado 15 de diciembre de 2019].
Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther. 2016; 7: 33-40.
Helsper CW, van Essen GA, Bonten MJ, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010; 27: 328-32.
http://aehve.org/objetivo-2021/[consultado 14 de diciembre de 2019]
European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2: 325-336.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published at Anales de la Real Academia de Cirugía y Medicina will have a Creative Commons Attribution 4.0 International License (CC BY 4.0).
The journal allow the authors to retain publisshing rights. Authors may reprint their articles in other media without habing to request authorization, provided they indicate that the article was originally published in Anales de la Real Academia de Cirugía y Medicina.